PureTech Health plc PRTCY
16.40 USD 0.00 (+0.00%)
At closeNov 12, 2026, 4:00 PM EST
17.09 Day range 17.09
13.93 52-week range 19.92
- YTD
- -1.47%
- 1 year
- +0.34%
News
businesswire.com PureTech Health Wins 2026 Prix Galien USA Award in Incubators, Accelerators and Equity Category BOSTON--(BUSINESS WIRE)--PureTech Health Wins 2026 Prix Galien USA Award in Incubators, Accelerators and Equity Category.
businesswire.com PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026 BOSTON--(BUSINESS WIRE)--PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory High-Risk Myelodysplastic Syndromes & Acute Myeloid Leukemia (AML) at ESMO 2026.
businesswire.com PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026 BOSTON--(BUSINESS WIRE)--PureTech Announces Presentation of Phase 1b Results for LYT-200 in R/R High-Risk Myelodysplastic Syndromes & Acute Myeloid Leukemia at ESMO 2026.
seekingalpha.com PureTech Health plc (PRTCY) Q2 2026 Earnings Call Transcript PureTech Health plc (PRTCY) Q2 2026 Earnings Call Transcript
marketbeat.com PureTech Health H1 Earnings Call Highlights PureTech Health NASDAQ: PRTC outlined progress across its portfolio in its 2026 half-year results call, highlighting external financings for Celea Therapeutics and Seaport Therapeutics, regulatory…
businesswire.com PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) BOSTON--(BUSINESS WIRE)--PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into…
businesswire.com PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress.